Streptomycin

CAFs were isolated as previously described.^{45 (link)} Briefly, tissue from early-stage IDC (stage 1) that was less than 10 mm in diameter was sliced and then digested overnight with a collagenase preparation (ISU ABXIS; Seoul, South Korea). Digested tissue was filtered through a 70 μm cell strainer (SPL Life Science; Pocheon-si, South Korea). Cells were separated by Ficoll gradients, washed with PBS, resuspended with DMEM/F12 cell culture medium containing 20% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 μg/ml streptomycin (Gibco BRL; Grand Island, NY, USA) and cultured at 37 °C in a humidified incubator containing 5% CO₂. The fibrotic nature of the isolated cells was confirmed by microscopic determination of morphology and immunofluorescence characterization using the antibodies against vimentin (Abcam; Cambridge, UK), cytokeratin (Dako; Glostrup, Denmark) and cytokeratin 5 (Novocastra; Newcastle upon Tyne, UK). Breast cancer cell lines (BT-474, MCF7, SK-BR-3, MDA-MB-231) were purchased from Korean Cell Line Bank (Seoul, South Korea) (authenticated using morphology and STR profiling) and cultured with DMEM cell culture medium containing 10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 μg/ml streptomycin at 37 °C in a humidified incubator containing 5% CO₂.

Human breast cancer cell lines (MCF-7 and MDA-MB-231) were purchased from the Korean Cell Line Bank (Seoul, South Korea), and they were cultivated in RPMI 1640 media supplemented with 10% fetal bovine serum, 1% penicillin, and streptomycin at 37ºC in a humidified incubator with 5% CO_2. RPMI 1640 medium, fetal bovine serum, phosphate buffered saline (PBS), and penincillin-streptomycin were obtained from Gibco, USA. Recombinant human CXCL10 was purchased from R&D systems (Minneapolis, MN).